178 results
DEFM14A
AGXRW
Agile Therapeutics Inc
25 Jul 24
Proxy related to merger
6:06am
authorized the Finance Committee of the Board (“Finance Committee”), which consisted of the independent directors, Sharon Barbari, Seth H.Z. Fischer and Dr … executing on its business plan if it remained independent, including the current and prospective business environment in which Agile operates
PREM14A
AGXRW
Agile Therapeutics Inc
12 Jul 24
Preliminary proxy related to merger
5:29pm
by Wainwright as placement agent. The Board also authorized the Finance Committee of the Board (“Finance Committee”), which consisted of the independent … to be subject to the risks and uncertainties of Agile executing on its business plan if it remained independent, including the current and prospective
DEFA14A
AGXRW
Agile Therapeutics Inc
26 Jun 24
Additional proxy soliciting materials
8:15am
to be contributed to by the Company for the benefit of any current or former employee, officer, director, retiree, independent contractor, or consultant … Documents, since January 1, 2021, neither the Company nor, to the knowledge of the Company, the Company’s independent registered public accounting firm has
8-K
EX-2.1
AGXRW
Agile Therapeutics Inc
26 Jun 24
Entry into a Material Definitive Agreement
8:00am
, retiree, independent contractor, or consultant of the Company, or any spouse or dependent of such individual, or under which the Company has or would … independent registered public accounting firm has identified or been made aware of (i) any material deficiencies or weaknesses in the design
8-K
EX-10.2
AGXRW
Agile Therapeutics Inc
26 Jun 24
Entry into a Material Definitive Agreement
8:00am
jurisdiction, shall not in any way be affected or impaired thereby. All covenants hereunder shall be given independent effect so that if a particular
8-K
EX-4.1
1jpg2n7yzrv
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-4.2
42bpkagl 6znsh
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-4.3
j7uh1mjnem2m5u
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm